Pacira BioSciences jumps 44.03% with RSI overbought on three charts

Pacira BioSciences has a bullish daily setup, but overbought readings make the distinction between trend support and immediate price support important. The hourly chart confirms the daily bias. Meanwhile, the 15-minute chart places the immediate decision zone around its pivot.

On Thursday, October 8, 2026, PCRX opened at $36.33 and traded between a low of $36.27 and a high of $36.33. It was trading at $36.295 as of 10:05 ET, up 44.03% from the previous close of $25.20, with 196,145 shares traded so far. The current session remains open. The daily candle opened at $36.33, traded between a low of $36.27 and a high of $36.33, and was last at $36.30, against a previous close of $25.20.

Key takeaways

• PCRX was trading at $36.295 as of 10:05 ET, up 44.03% from the previous close of $25.20, with 196,145 shares traded.
• Daily RSI14 is 84.98 (up from 50.91 in the previous session), hourly RSI14 is 90.74, and 15-minute RSI14 is 94.38 — all in overbought territory.
• Price sits above the daily 20-session EMA at $26.16, 50-session EMA at $25.51, and 200-session EMA at $24.46, maintaining bullish alignment.
• The daily MACD line stands at 0.87, above its signal at 0.14, with a positive histogram of 0.72.
• Price is below the 15-minute pivot at $36.3 and first resistance at $36.31, but above first support at $36.29, marking the immediate decision zone.

Pacira BioSciences news reported before Thursday’s session

A Seeking Alpha report published before Thursday’s open said Viatris would acquire Pacira for $36.50 per share in cash. Seeking Alpha valued the proposed deal at $1.65 billion and reported an expected completion by the end of 2026. Investing.com also reported the proposed $1.65 billion acquisition before Thursday’s open.

Separately, Yahoo Finance reported on October 6, 2026, that Pacira had signed a partnership with Italy-based Molteni Farmaceutici. The report said Molteni received exclusive distribution rights for EXPAREL, Pacira’s non-opioid postsurgical pain drug, across several European countries. Investing.com had reported the European expansion partnership on October 5, 2026. These reports were published before Thursday’s session.

Daily trend support is bullish, with daily RSI14 at 84.98

PCRX’s daily averages are bullishly aligned beneath price: the 20-session EMA is $26.16, the 50-session EMA is $25.51, and the 200-session EMA is $24.46. That ordering supports the main bullish bias. However, price also sits above the daily upper Bollinger Band at $30.52, placing it outside the current band envelope.

Daily RSI14 rose to 84.98 from 50.91 in the previous session, leaving it in overbought territory. These readings support the bullish direction, while RSI flags overbought conditions rather than a bearish signal by itself.

At the same time, daily ATR14 increased to $1.56 from $0.83, indicating greater measured volatility than in the preceding session. Price is above the daily first resistance at $25.8, the pivot at $25.4, and first support at $24.79. Those levels come from the previous completed daily candle and apply to the current session. They sit below the immediate trading area.

Hourly confirmation and 15-minute timing

Hourly chart reinforces the bullish bias

Meanwhile, PCRX’s hourly chart confirms the daily view. Price is above the bullishly aligned 20-hour EMA at $26.24, 50-hour EMA at $25.57, and 200-hour EMA at $25.13. Hourly RSI14 is 90.74, also overbought. The MACD line at 0.94 exceeds its signal at 0.2, with a positive histogram of 0.74. Price is above the hourly upper Bollinger Band at $30.57 and the hourly pivot at $25.18. There is no directional disagreement here, but the hourly readings reinforce the overbought caveat.

15-minute chart defines the immediate decision zone

For short-term execution context, price sits below the 15-minute pivot at $36.3 and first resistance at $36.31, but above first support at $36.29. It also stands above the 15-minute upper Bollinger Band at $34.84 and the 20-quarter-hour EMA at $28.19. The 15-minute RSI14 is 94.38, in overbought territory, while its MACD histogram is positive at 1.25. In contrast to daily ATR, 15-minute ATR14 fell to $0.82 from $0.89. That comparison describes local volatility, not a change in the daily bias.

Bullish and bearish conditions

The bullish scenario requires holding the 15-minute first support at $36.29, then clearing the pivot at $36.3 and first resistance at $36.31. A move above the session high of $36.33 would further support that case. The daily and hourly average structures remain its broader technical foundation.

Conversely, a break below $36.29 followed by the session low at $36.27 would undermine the immediate bullish case. Below those levels, the 15-minute upper band at $34.84 provides a lower reference. The hourly upper band at $30.57 and daily upper band at $30.52 follow. Such weakness would not automatically reverse the daily bias. A break below the daily 20-session EMA at $26.16 would challenge that broader structure more directly.

Overall, PCRX stands between nearby 15-minute support and its pivot, while remaining above its daily trend averages and upper Bollinger Band. Daily measured volatility has increased, and all three RSI readings are overbought. The unresolved question is whether the nearby support levels can hold through the still-open session.

FAQ

What are the key technical levels to watch for PCRX?

The 15-minute first support at $36.29, pivot at $36.3, and first resistance at $36.31 form the immediate decision zone. The session high at $36.33 marks a nearby upside reference. On the downside, the 15-minute upper Bollinger Band at $34.84, hourly upper band at $30.57, and daily upper band at $30.52 provide lower references. The daily 20-session EMA at $26.16 is the broader trend foundation.

Is PCRX overbought?

Yes, across all three timeframes. The daily RSI14 is 84.98, up from 50.91 in the previous session. The hourly RSI14 is 90.74. The 15-minute RSI14 is 94.38. All three readings are well into overbought territory, though overbought RSI alone does not signal a bearish reversal.

What do the moving averages indicate about PCRX’s trend?

The daily moving averages are bullishly aligned: the 20-session EMA at $26.16 sits above the 50-session EMA at $25.51, which sits above the 200-session EMA at $24.46. Price at $36.295 is above all three, confirming a bullish daily trend structure. The hourly EMAs show the same bullish alignment.

What acquisition news has been reported for Pacira BioSciences?

Before Thursday’s open, Seeking Alpha reported that Viatris would acquire Pacira BioSciences for $36.50 per share in cash, while Investing.com reported the $1.65 billion deal. Seeking Alpha valued the proposed deal at $1.65 billion and reported an expected completion by the end of 2026.

{"@context":"","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What are the key technical levels to watch for PCRX?","acceptedAnswer":{"@type":"Answer","text":"The 15-minute first support at $36.29, pivot at $36.3, and first resistance at $36.31 form the immediate decision zone. The session high at $36.33 marks a nearby upside reference. On the downside, the 15-minute upper Bollinger Band at $34.84, hourly upper band at $30.57, and daily upper band at $30.52 provide lower references. The daily 20-session EMA at $26.16 is the broader trend foundation."}},{"@type":"Question","name":"Is PCRX overbought?","acceptedAnswer":{"@type":"Answer","text":"Yes, across all three timeframes. The daily RSI14 is 84.98, up from 50.91 in the previous session. The hourly RSI14 is 90.74. The 15-minute RSI14 is 94.38. All three readings are well into overbought territory, though overbought RSI alone does not signal a bearish reversal."}},{"@type":"Question","name":"What do the moving averages indicate about PCRX's trend?","acceptedAnswer":{"@type":"Answer","text":"The daily moving averages are bullishly aligned: the 20-session EMA at $26.16 sits above the 50-session EMA at $25.51, which sits above the 200-session EMA at $24.46. Price at $36.295 is above all three, confirming a bullish daily trend structure. The hourly EMAs show the same bullish alignment."}},{"@type":"Question","name":"What acquisition news has been reported for Pacira BioSciences?","acceptedAnswer":{"@type":"Answer","text":"Before Thursday's open, Seeking Alpha reported that Viatris would acquire Pacira BioSciences for $36.50 per share in cash, while Investing.com reported the $1.65 billion deal. Seeking Alpha valued the proposed deal at $1.65 billion and reported an expected completion by the end of 2026."}}]}

Article produced with the assistance of artificial intelligence and reviewed by the editorial team.